Drugs / RC288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07537881 | Apr 2026 → Dec 2029 expected | cancer | RemeGen Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07537881 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of RC288.” NCT07537881 ↗ |